May 2025
1. IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al
   Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
   BMJ. 2025;389:e081165.
   

   >> Share

   
   January 2024
2. MAHASE E
   Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.
   BMJ. 2024;384:q59.
   

   >> Share

   
   August 2023
3. LANG K
   How do we best use Paxlovid and other covid antivirals?
   BMJ. 2023;382:p1666.
   

   >> Share

   
   July 2022
4. TANNE JH
   Covid-19: FDA authorises pharmacists to prescribe Paxlovid.
   BMJ. 2022;378:o1695.
   

   >> Share

   
   June 2022
5. PHIZACKERLEY D
   Three more points about Paxlovid for covid-19.
   BMJ. 2022;377:o1397.
   

   >> Share

   
   May 2022
6. MONEER O, Daly G, Skydel JJ, Nyhan K, et al
   Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
   BMJ. 2022;377:e069400.
   

   >> Share

   
   April 2022
7. EXTANCE A
   Covid-19: What is the evidence for the antiviral Paxlovid?
   BMJ. 2022;377:o1037.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share